We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Ruling Secures GSK’s ‘467 Patent Term on Avodart and Jalyn
Court Ruling Secures GSK’s ‘467 Patent Term on Avodart and Jalyn
August 27, 2013
Mylan, Roxane and a handful of other generic drugmakers have not proven “by clear and convincing evidence” that GlaxoSmithKline’s (GSK) ‘467 patent protecting its prostate treatments Avodart and Jalyn are invalid, a federal judge has ruled.